pde4 inhibitors offer novel therapeutic strategies respiratory diseases including asthma chronic obstructive pulmonary disease selective pde4 inhibitors provide therapeutic option infants bronchopulmonary dysplasia bpd effect pde4 inhibitors investigated rat model lung injury rat pups exposed room air hyperoxia hyperoxia pde4 inhibitors rolipram piclamilast effects prolonged pde4 inhibitor therapy investigated studying survival histopathology fibrin deposition alveolar vascular leakage differential mrna expression rtpcr key genes involved inflammation alveolar enlargement coagulation fibrinolysis pde4 inhibitor therapy prolonged median survival NUMBER days reduced alveolar fibrin deposition lung inflammation vascular leakage decreasing influx monocytes macrophages protein efflux bronchoalveolar lavage fluid analysis mrna expression key genes involved experimental bpd revealed significant pde4 improvement genes involved inflammation fibrin deposition alveolarisation conclusion inhibition prolongs survival inhibiting inflammation reducing alveolar fibrin deposition rat pups neonatal hyperoxic lung injury piclamilast outperformed rolipram phosphodiesterase NUMBER pre term anti inflammatory pre term hyperoxia induced pre term anti inflammatory real time inhibitor induced phosphodiesterase NUMBER pre term